Cargando…

Fibroblasts in fibrosis: novel roles and mediators

Fibroblasts are the most common cell type of the connective tissues found throughout the body and the principal source of the extensive extracellular matrix (ECM) characteristic of these tissues. They are also the central mediators of the pathological fibrotic accumulation of ECM and the cellular pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Kendall, Ryan T., Feghali-Bostwick, Carol A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4034148/
https://www.ncbi.nlm.nih.gov/pubmed/24904424
http://dx.doi.org/10.3389/fphar.2014.00123
_version_ 1782317935824470016
author Kendall, Ryan T.
Feghali-Bostwick, Carol A.
author_facet Kendall, Ryan T.
Feghali-Bostwick, Carol A.
author_sort Kendall, Ryan T.
collection PubMed
description Fibroblasts are the most common cell type of the connective tissues found throughout the body and the principal source of the extensive extracellular matrix (ECM) characteristic of these tissues. They are also the central mediators of the pathological fibrotic accumulation of ECM and the cellular proliferation and differentiation that occurs in response to prolonged tissue injury and chronic inflammation. The transformation of the fibroblast cell lineage involves classical developmental signaling programs and includes a surprisingly diverse range of precursor cell types—most notably, myofibroblasts that are the apex of the fibrotic phenotype. Myofibroblasts display exaggerated ECM production; constitutively secrete and are hypersensitive to chemical signals such as cytokines, chemokines, and growth factors; and are endowed with a contractile apparatus allowing them to manipulate the ECM fibers physically to close open wounds. In addition to ECM production, fibroblasts have multiple concomitant biological roles, such as in wound healing, inflammation, and angiogenesis, which are each interwoven with the process of fibrosis. We now recognize many common fibroblast-related features across various physiological and pathological protracted processes. Indeed, a new appreciation has emerged for the role of non-cancerous fibroblast interactions with tumors in cancer progression. Although the predominant current clinical treatments of fibrosis involve non-specific immunosuppressive and anti-proliferative drugs, a variety of potential therapies under investigation specifically target fibroblast biology.
format Online
Article
Text
id pubmed-4034148
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-40341482014-06-05 Fibroblasts in fibrosis: novel roles and mediators Kendall, Ryan T. Feghali-Bostwick, Carol A. Front Pharmacol Pharmacology Fibroblasts are the most common cell type of the connective tissues found throughout the body and the principal source of the extensive extracellular matrix (ECM) characteristic of these tissues. They are also the central mediators of the pathological fibrotic accumulation of ECM and the cellular proliferation and differentiation that occurs in response to prolonged tissue injury and chronic inflammation. The transformation of the fibroblast cell lineage involves classical developmental signaling programs and includes a surprisingly diverse range of precursor cell types—most notably, myofibroblasts that are the apex of the fibrotic phenotype. Myofibroblasts display exaggerated ECM production; constitutively secrete and are hypersensitive to chemical signals such as cytokines, chemokines, and growth factors; and are endowed with a contractile apparatus allowing them to manipulate the ECM fibers physically to close open wounds. In addition to ECM production, fibroblasts have multiple concomitant biological roles, such as in wound healing, inflammation, and angiogenesis, which are each interwoven with the process of fibrosis. We now recognize many common fibroblast-related features across various physiological and pathological protracted processes. Indeed, a new appreciation has emerged for the role of non-cancerous fibroblast interactions with tumors in cancer progression. Although the predominant current clinical treatments of fibrosis involve non-specific immunosuppressive and anti-proliferative drugs, a variety of potential therapies under investigation specifically target fibroblast biology. Frontiers Media S.A. 2014-05-27 /pmc/articles/PMC4034148/ /pubmed/24904424 http://dx.doi.org/10.3389/fphar.2014.00123 Text en Copyright © 2014 Kendall and Feghali-Bostwick. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Kendall, Ryan T.
Feghali-Bostwick, Carol A.
Fibroblasts in fibrosis: novel roles and mediators
title Fibroblasts in fibrosis: novel roles and mediators
title_full Fibroblasts in fibrosis: novel roles and mediators
title_fullStr Fibroblasts in fibrosis: novel roles and mediators
title_full_unstemmed Fibroblasts in fibrosis: novel roles and mediators
title_short Fibroblasts in fibrosis: novel roles and mediators
title_sort fibroblasts in fibrosis: novel roles and mediators
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4034148/
https://www.ncbi.nlm.nih.gov/pubmed/24904424
http://dx.doi.org/10.3389/fphar.2014.00123
work_keys_str_mv AT kendallryant fibroblastsinfibrosisnovelrolesandmediators
AT feghalibostwickcarola fibroblastsinfibrosisnovelrolesandmediators